Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Ongoing Lung Decline With Age Intensified Response (OLD AIR)

30 juni 2026 uppdaterad av: Samuel Cohen, MD, Cedars-Sinai Medical Center

A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)

This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course "hit-and-run" dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

This Phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the effects of fisetin, a naturally occurring flavonoid with senolytic properties, on pulmonary health in older adults. Aging and cigarette smoke exposure have both been associated with cellular senescence, a biological process characterized by the accumulation of dysfunctional cells that may contribute to progressive decline in organ function. The study investigates whether intermittent administration of fisetin can favorably influence lung physiology and biological markers associated with aging.

Participants will be randomized to receive either fisetin or placebo and will undergo a short-course treatment regimen using a "hit-and-run" approach intended to transiently target senescent cells. The study population includes older adults with and without a history of cigarette smoking to allow assessment across groups with differing risk for accelerated pulmonary aging.

Study procedures include clinical evaluations, pulmonary function testing, exercise-based assessments, electrocardiography, laboratory testing, and collection of blood and urine samples for analysis of biomarkers related to cellular senescence and aging. Participants will be followed over a two-week study period, during which safety, tolerability, and protocol feasibility will be assessed. The results of this pilot study are intended to inform the design of future trials evaluating senolytic therapies as potential interventions for age-related declines in lung function and health.

Studietyp

Interventionell

Inskrivning (Beräknad)

40

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

  • Adults aged 60 years and older who are physically capable of participating in study procedures;
  • Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (<5-pound change);
  • No blood donation within 2 months before screening; absence of unstable chronic disease;
  • Willing to maintain baseline activity level throughout the study;
  • Body mass index <30 kg/m²;
  • Either a history of at least 10 pack-years of cigarette smoking or never-smoking status.

Exclusion Criteria:

  • Electrocardiogram (ECG) abnormalities, including prolonged QTc.
  • Use of fisetin, other flavonoid supplements, or known senolytic compounds within 6 months prior to screening.
  • Resting systolic blood pressure >160 mmHg or diastolic blood pressure >110 mmHg.
  • Known allergy or hypersensitivity to fisetin or any component of the study product.
  • Active malignancy, except non-melanoma skin cancer.
  • Clinically significant hepatic, renal, cardiovascular, endocrine, immunologic, metabolic, or other uncontrolled medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results.
  • Clinically significant laboratory abnormalities, including severe anemia, leukopenia, thrombocytopenia, uncontrolled diabetes, advanced kidney disease, significant liver dysfunction, or evidence of systemic inflammation.
  • Human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C infection, or invasive fungal infection.
  • History of diverticulitis or diverticulosis with gastrointestinal bleeding.
  • Current use of systemic corticosteroids.
  • Current use of warfarin.
  • Current use of medications with significant interaction potential with fisetin, including selected CYP450 or transporter substrates, inhibitors, or inducers, unless such medications can be safely withheld according to protocol requirements.
  • Recent medication, supplement, or lifestyle changes that may affect study outcomes, in the opinion of the investigator.
  • Inability to perform required study procedures, including pulmonary function testing, exercise testing, or other protocol assessments.
  • Unwillingness or inability to provide informed consent.
  • Pregnancy or breastfeeding.
  • Any other condition that, in the opinion of the investigator, would make participation unsafe or compromise study integrity.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Fisetin
Participants receive oral fisetin at approximately 20 mg/kg/day for 2 consecutive days on Days 1-2 and again on Days 8-9 using a senolytic "hit-and-run" dosing strategy.
Participants randomized to the experimental arm will receive oral fisetin capsules administered at a target dose of approximately 20 mg/kg/day for 2 consecutive days on Days 1-2 and again on Days 8-9. Fisetin will be supplied as 100 mg capsules and dosed according to body weight using a senolytic "hit-and-run" treatment approach.
Placebo-jämförare: Placebo
Participants receive matching placebo capsules administered on the same schedule as the fisetin arm (Days 1-2 and Days 8-9).
Participants randomized to the control arm will receive matching placebo capsules administered orally on the same schedule as the fisetin arm (Days 1-2 and Days 8-9). Placebo will be used to maintain blinding and permit comparison of efficacy and safety outcomes between treatment groups.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Forced Vital Capacity (FVC)
Tidsram: Baseline and Day 14
Forced vital capacity measured by spirometry to assess lung function following treatment with fisetin versus placebo.
Baseline and Day 14
Forced Expiratory Volume in 1 Second (FEV1)
Tidsram: Baseline and Day 14
Forced expiratory volume in one second measured by spirometry following treatment with fisetin versus placebo.
Baseline and Day 14
FEV1/FVC Ratio
Tidsram: Baseline and Day 14
Ratio of FEV1 to FVC measured by spirometry following treatment with fisetin versus placebo.
Baseline and Day 14

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
6-Minute Walk Distance (6MWD)
Tidsram: Baseline and Day 14
Change in distance walked during a standardized 6-minute walk test, with pulse oximetry monitoring before and after the test.
Baseline and Day 14
Peak Oxygen Uptake (VO₂)
Tidsram: Baseline and Day 14
Change in peak oxygen uptake measured during cardiopulmonary exercise testing (CPET) as an assessment of exercise capacity and cardiopulmonary fitness.
Baseline and Day 14
Biomarkers of Cellular Senescence
Tidsram: Baseline and Day 14
Change in circulating biomarkers associated with cellular senescence measured from blood samples collected before and after treatment.
Baseline and Day 14

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 juni 2026

Primärt slutförande (Beräknad)

16 juni 2027

Avslutad studie (Beräknad)

15 juli 2027

Studieregistreringsdatum

Först inskickad

24 juni 2026

Först inskickad som uppfyllde QC-kriterierna

24 juni 2026

Första postat (Faktisk)

30 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

1 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • STUDY00003866

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data collected during this study will not be made publicly available. De-identified aggregate study results may be reported in publications and presentations. Requests for additional data may be considered by the Principal Investigator on a case-by-case basis and in accordance with applicable institutional policies, participant consent, privacy regulations, and IRB requirements.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera